In the Asia-Pacific medical devices industry, there were 6 private equity deals announced in Q4 2023, worth a total value of $165.4m, according to GlobalData’s Deals Database. The $150m Management Buy-in (MBI) Pacific Smiles Group by Pacific Smiles Group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Medical Devices Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Asia-Pacific decreased by 72% in Q4 2023 compared with the previous quarter’s total of $600m and fell by 92% as compared to Q4 2022. Related deal volume increased by 200% in Q4 2023 versus the previous quarter and was 20% higher than in Q4 2022.
The top-ranked financial advisors supporting these private equity deals in Asia-Pacific in Q4 2023 were Bank of America; T. Rowe Price Group; UBS Group with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Asia-Pacific Q4 2023 were Akin Gump Strauss Hauer & Feld; Ashurst; Kirkland & Ellis with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Medical Devices Industry Mergers And Acquisitions Deals By Top Themes In 2023 – Thematic Intelligence, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.